Heterogeneity of the lymphokine-activated killer cell phenotype
โ Scribed by Brian S. Chadwick; Richard G. Miller
- Book ID
- 113134679
- Publisher
- Elsevier Science
- Year
- 1991
- Tongue
- English
- Weight
- 632 KB
- Volume
- 132
- Category
- Article
- ISSN
- 0008-8749
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Adoptive immunotherapy is a novel approach to treating patients with cancer, utilizing as therapy a patient's own peripheral blood lymphocytes that have been activated by incubation with interleukin-2 (IL-2). These cells develop the ability to mediate tumor regression in vivo and are referred to as
Lymphokine-activated killer (LAK) cells are generated by the culture of peripheral blood lymphocytes with interleukin-2 (IL-2). A variety of cells, including T-lymphocytes and natural killer (NK) cells, can be activated by IL-2 to exhibit the ability to kill multiple tumor and "modified-self" target
Adoptive transfer of autologous lymphokine-activated killer cells (LAK) in conjunction with recombinant interleukin-2 (rIL-2) has been reported to produce significant regression in metastatic disease in patients with advanced cancer. In an effort to confirm the results reported by the Surgery Branch